News
Crypto Meets Wall Street: MEXC Unveils 'Real Stocks' with 0-Fee U. S. Equity Trading and Real Dividends
1+ hour, 4+ min ago (170+ words) May 31, 2026, 22: 00 ET Campaign 2: $1, 000, 000 Stock Prize Pool (June 2 " June 16)During the campaign period, U. S. stock spot trading is available at zero fees. Complete trading tasks to share in a 1, 000, 000 USD equivalent stock prize pool. Campaign 3: Real-Time Market Data Subsidy for New Deposits…...
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
2+ hour, 15+ min ago (172+ words) May 31, 2026, 20: 48 ET SEOUL, South Korea, June 1, 2026 /PRNewswire/ -- Hanmi Pharm. Co. , Ltd. ("Hanmi") today announced that they have entered into a license agreement for the development, manufacturing and commercialization of Hanmi's biologic drug candidate sonefpeglutide (LAPSGLP-2 analog) with Eli Lilly and…...
Tium Bio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026
3+ hour, 34+ min ago (608+ words) PR Newswire - 75. 0% Response Rate and Median PFS of 10. 9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC) - Advancing Tosposertib Toward Next-Stage Development as a Potential Best-in-Class Treatment Option SEONGNAM, South Korea, May 31, 2026 /PRNewswire/ -- Tium Bio…...
D3 Bio Presents First-Line Data for Elisrasib (D3 S-001) at ASCO 2026; Next-Generation KRAS G12 C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
3+ hour, 4+ min ago (310+ words) May 31, 2026, 20: 00 ET Elisrasib monotherapy delivers an ORR of 78. 0% and median PFS of 12. 4 months in first-line KRAS G12 C'mutant NSCLC (n=41) across all PD-L1 expression levels Combination of elisrasib with pembrolizumab achieves an ORR of 81. 3% in first-line KRAS G12 C'mutant NSCLC (n=48) across…...
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
2+ hour, 49+ min ago (700+ words) PR Newswire SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171. HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18. 2), as sequential…...
Traveloka 6. 6 Mid Year Sale: Up to S$66 Off Flights, Hotels and Attractions for Singapore Travelers
2+ hour, 4+ min ago (285+ words) 01 Jun, 2026, 09: 00 CST Traveloka's 6. 6 Mid Year Sale Unlocks $66 Sitewide Discounts and 1-for-1 Attraction Deals SINGAPORE, June 1, 2026 /PRNewswire/ -- Traveloka, Southeast Asia's leading travel tech platform, today announced its 6. 6 Mid Year Sale that runs from 2 to 9 June 2026, offering Singapore travelers up to S…...
UOB and FPT sign Mo U to advance AI, technology transformation and financial innovation opportunities
2+ hour, 4+ min ago (180+ words) 01 Jun, 2026, 09: 00 CST The Mo U exchange ceremony took place at the Vietnam - Singapore Tech Connect Forum during General Secretary of the Communist Party of Vietnam and President of the Socialist Republic of Vietnam To Lam's official visit to Singapore. UOB…...
2026 ASCO | Innovent Presents Preliminary Po C Data of IBI363 (TAK-928) PD-1/IL-2-bias bispecific fusion protein) in First-line Advanced NSCLC
3+ hour, 4+ min ago (473+ words) May 31, 2026, 20: 00 ET This study is the first stage of a Po C clinical study conducted in China, to evaluate the'safety, efficacy, and dose optimization strategy of IBI363 in combination with platinum-based doublet chemotherapy (PDC) in previously untreated patients with locally advanced…...
Imm Vira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
3+ hour, 4+ min ago (548+ words) PR Newswire SUZHOU, China, May 31, 2026 /PRNewswire/ -- Imm Vira Group ("Imm Vira") today announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. As of…...
Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO" (vorasidenib) at ASCO 2026
5+ hour, 28+ min ago (794+ words) May 31, 2026, 17: 36 ET A global, randomized, double-blinded, Phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an IDH1/2 mutation (INDIGO): updated efficacy and safety " Sunday, May 31, 4: 36 - 4: 42 p. m. CDT Key findings, which were presented by Timothy Cloughesy, M. D. , David Geffen School of…...